ABOS: Phase II data for a novel Alzheimer's antibody and brain delivery tech are expected by Q4 and 2027
The discussion highlighted progress on sabirnetug, a selective Aβ oligomer antibody for early Alzheimer's, with phase II data expected in Q4. The Enhanced Brain Delivery program, leveraging JCR's technology, aims for an IND in mid-2027. Strong clinical retention and biomarker data support optimism…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.